Tofacitinib 5 mg Twice Daily in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs: A Comprehensive Review of Phase 3 Efficacy and Safety

BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We performed a comprehensive review of phase 3 studies of tofacitinib 5 mg twice daily (BID) (approved dose in many countries) in patients with moderate to severe RA and inadequate response to p...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Clin Rheumatol
Päätekijät: Bird, Paul, Bensen, William, El-Zorkany, Bassel, Kaine, Jeffrey, Manapat-Reyes, Bernadette Heizel, Pascual-Ramos, Virginia, Witcombe, David, Soma, Koshika, Zhang, Richard, Thirunavukkarasu, Krishan
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Lippincott Williams & Wilkins 2019
Aiheet:
Original Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6445596/
https://ncbi.nlm.nih.gov/pubmed/29794874
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/RHU.0000000000000786
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia